Thera-SAbDab

RANIBIZUMAB

>   Structural Summary
TherapeuticRanibizumab
TargetVEGFA
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS
Light ChainDIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK
100% seqID Fv Structure1cz8 [Fvs: HL, YX]
99% seqID Fv StructureNone
95-98% seqID Fv Structure1bj1 [Fvs: HL, KJ], 6bft [Fvs: AB, HL], 7v5n [Fvs: BA, FE]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Ranibizumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 97.83%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 101 102 103 104 105 106 107 108 109 110 111 112 113
ranibizumab E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y D F T H Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P Y Y Y G T S H W Y F D V W G Q G T L V T V S S
1bj1 E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y T F T N Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P H Y Y G S S H W Y F D V W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
ranibizumab D I Q L T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
1bj1 D I Q M T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
Sequence identity: 97.83%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 101 102 103 104 105 106 107 108 109 110 111 112 113
ranibizumab E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y D F T H Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P Y Y Y G T S H W Y F D V W G Q G T L V T V S S
7v5n E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y T F T N Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P H Y Y G S S H W Y F D V W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
ranibizumab D I Q L T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
7v5n D I Q M T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
Sequence identity: 96.96%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 101 102 103 104 105 106 107 108 109 110 111 112 113
ranibizumab E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y D F T H Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P Y Y Y G T S H W Y F D V W G Q G T L V T V S S
6bft E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y D F D N Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P H Y Y G S S H W Y F D V W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
ranibizumab D I Q L T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
6bft D I Q M T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T D D L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
>   Metadata
FormatFab
IsotypeG1
Highest Clinical Trial (August '23)Approved
Estimated Status (August '23)Active
Recorded Developmental Technology
INN Year Proposed2004
INN Year Recommended2004
Companies InvolvedGenentech, Manhattan Eye Ear & Throat Hospital, Novartis Ophthalmics, University of Bonn
Conditions ApprovedChoroidal neovascularisation, Degenerative myopia, Diabetic macular oedema, Retinal oedema, Wet age-related macular degeneration, Diabetic retinopathy
Conditions ActiveRetinopathy of prematurity, Polypoidal choroidal vasculopathy
Conditions DiscontinuedRetinal telangiectasis
NotesBiosimilars available

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy